Jump to content

Page values for "Topiramate"

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringTopiramate
brandStringTopamax (IR), Trokendi XR, Qudexy XR, Eprontia (oral solution); component of Qsymia (with phentermine)
structureFile
classesList of String, delimiter: ,[[:Category:Anticonvulsants|Anticonvulsant]] [[:Category:Migraine prophylactics|Migraine prophylactic]] [[:Category:Weight loss medicines|Weight loss medicine]] [[:Category:Sodium channel blockers|Sodium channel blocker]]
mechanismString
usesString'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"'
starting_doseStringMigraine: 25 mg PO at bedtime, titrate by 25 mg weekly to target 100 mg/day divided BID. Seizures: 25-50 mg/day, titrate weekly to 200-400 mg/day divided BID
preparationsStringIR tablets 25, 50, 100, 200 mg; sprinkle capsules 15, 25 mg; Trokendi XR capsules 25, 50, 100, 200 mg; Qudexy XR capsules; Eprontia oral solution 25 mg/mL
fda_maxString1600 mg/day (theoretical seizure dosing); practical use 400 mg/day for seizures, 100-200 mg/day for migraine prophylaxis
pill_idText
routesList of String, delimiter: ,Oral
onsetStringAnticonvulsant effect within days at therapeutic level; migraine prophylaxis effect emerges over 2-3 months
durationString12-24 hours (IR BID); 24 hours (ER once-daily)
halflifeString~21 hours'"`UNIQ--ref-00000028-QINU`"'
bioavailabilityString~80% (oral)'"`UNIQ--ref-00000029-QINU`"'
pregnancyString'''Substantial teratogenic risk''' including cleft lip/palate, hypospadias, and growth restriction (pregnancy registry data clear); effective contraception and pre-pregnancy counseling are required in reproductive-age patients'"`UNIQ--ref-0000002A-QINU`"'
legalString[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance'"`UNIQ--ref-0000002B-QINU`"'